RecruitingPhase 1NCT06799520

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

A Phase 1 Open-label Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Subcutaneous VIS171 in Participants With Autoimmune Disease(s)

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Enrollment

30 participants

Start Date

Mar 17, 2025

Study Type

INTERVENTIONAL

Conditions

Systemic Lupus Erythematosus (SLE)Alopecia Areata (AA)Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)

Summary

The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s). The total duration of the clinical trial for each participant will be up to approximately 9 to 12 months.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called VIS171 for people with alopecia areata (aa), immune-mediated focal segmental glomerulosclerosis (fsgs), and other related conditions. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.